Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: dopamine transporter inhibitors - Alseres Pharmaceuticals

Drug Profile

Research programme: dopamine transporter inhibitors - Alseres Pharmaceuticals

Alternative Names: BLS 0605; DAT blockers - Alseres Pharmaceuticals; Dopamine reuptake inhibitors - Alseres Pharmaceuticals; O-1369

Latest Information Update: 12 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Alseres Pharmaceuticals
  • Class Small molecules; Tropanes
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 12 Mar 2008 Pharmacokinetics data from a preclinical trial released by Alseres Pharmaceuticals
  • 21 Aug 2007 Preclinical development is ongoing
  • 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top